【康方生物(09926.HK):依达方®(依沃西,PD-1/VEGF)第二个适应症上市申请获得NMPA批准 用于一线治疗PD-L1阳性NSCLC】康方生物(09926.HK)发布公告,由公司自主研发的全球首创双特异性抗体依达方®(依沃西,PD-1/VEGF)单药用于PD-L1阳性(TPS≥1%)的表皮生长因子受体(EGFR)基因突变阴性和间变性淋巴瘤激酶(ALK)阴性的局部晚期或转移性非小细胞肺癌(NSCLC)的一线治疗的新药上市申请(sNDA),已获得中国国家药品监督管理局(NMPA)批准上市。这是依沃西获批上市的第二个适应症,让中国患者“率先用上全球最优治疗方案”成为现实。

金融界
27 Apr
康方生物(09926.HK)发布公告,由公司自主研发的全球首创双特异性抗体依达方®(依沃西,PD-1/VEGF)单药用于PD-L1阳性(TPS≥1%)的表皮生长因子受体(EGFR)基因突变阴性和间变性淋巴瘤激酶(ALK)阴性的局部晚期或转移性非小细胞肺癌(NSCLC)的一线治疗的新药上市申请(sNDA),已获得中国国家药品监督管理局(NMPA)批准上市。这是依沃西获批上市的第二个适应症,让中国患者“率先用上全球最优治疗方案”成为现实。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10